Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects

Inclusion Criteria: * Healthy subjects aged 18 to 65 years * Body mass index (BMI) between 18.5 und 30 kg/m2 * Subject is judged to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests * Subject has no evidence of clinically significant abnormality on echocardiogram (ECG) performed at screening visit and/or prior to administration of the study drug * Non-Smoker * Subjects providing informed consent Exclusion Criteria: * Subjects with known hypersensitivity to study medication * Subjects who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) * Subjects with a history of peptic ulcer disease and/or gastrointestinal bleeding * Pregnant women (pregnancy rapid assay required for women with childbearing potential), women currently breast-feeding, or with the intention to breast-feed * History or evidence of active malignancy within the 24 months prior to entry. * Subject has a history of fainting during blood draws. * Subject has had major surgery, donated or lost 1 unit of blood (approximately 500 ml) in the last 4 weeks * Subject is currently a regular user (including "recreational use) of illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years. * Active or history of drug abuse, * Chronic or acute renal, hepatic or metabolic disorder * Participation in a clinical study within 30 days pr…